Guselkumab
Indication
Treating active psoriatic arthritis after inadequate response to DMARDs - NICE TA815
NICE TA815 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
Brand:
Nice TA:
815
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
1.1 Guselkumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have had 2 conventional DMARDs and:
-
have had at least 1 biological DMARD, or
-
tumour necrosis factor (TNF)-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Guselkumab is recommended only if the company provides it according to the commercial arrangement. Active psoriatic arthritis is defined as peripheral arthritis with 3 or more tender joints and 3 or more swollen joints.